JP7426121B2 - Ｃｘｃｒ３の切断可能な活性化因子および使用方法 - Google Patents

Ｃｘｃｒ３の切断可能な活性化因子および使用方法 Download PDF

Info

Publication number
JP7426121B2
JP7426121B2 JP2021521472A JP2021521472A JP7426121B2 JP 7426121 B2 JP7426121 B2 JP 7426121B2 JP 2021521472 A JP2021521472 A JP 2021521472A JP 2021521472 A JP2021521472 A JP 2021521472A JP 7426121 B2 JP7426121 B2 JP 7426121B2
Authority
JP
Japan
Prior art keywords
peptide
amino acid
cxcl
recombinant
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021521472A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022512770A5 (enExample
JP2022512770A (ja
Inventor
アラン エイチ． ウェルズ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pittsburgh
Original Assignee
University of Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pittsburgh filed Critical University of Pittsburgh
Publication of JP2022512770A publication Critical patent/JP2022512770A/ja
Publication of JP2022512770A5 publication Critical patent/JP2022512770A5/ja
Priority to JP2023198254A priority Critical patent/JP7798368B2/ja
Application granted granted Critical
Publication of JP7426121B2 publication Critical patent/JP7426121B2/ja
Priority to JP2025145434A priority patent/JP2025172140A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2021521472A 2018-10-22 2019-10-18 Ｃｘｃｒ３の切断可能な活性化因子および使用方法 Active JP7426121B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023198254A JP7798368B2 (ja) 2018-10-22 2023-11-22 Ｃｘｃｒ３の切断可能な活性化因子および使用方法
JP2025145434A JP2025172140A (ja) 2018-10-22 2025-09-02 Ｃｘｃｒ３の切断可能な活性化因子および使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862748711P 2018-10-22 2018-10-22
US62/748,711 2018-10-22
PCT/US2019/056955 WO2020086400A1 (en) 2018-10-22 2019-10-18 Cleavable activators of cxcr3 and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023198254A Division JP7798368B2 (ja) 2018-10-22 2023-11-22 Ｃｘｃｒ３の切断可能な活性化因子および使用方法

Publications (3)

Publication Number Publication Date
JP2022512770A JP2022512770A (ja) 2022-02-07
JP2022512770A5 JP2022512770A5 (enExample) 2022-10-17
JP7426121B2 true JP7426121B2 (ja) 2024-02-01

Family

ID=70330587

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021521472A Active JP7426121B2 (ja) 2018-10-22 2019-10-18 Ｃｘｃｒ３の切断可能な活性化因子および使用方法
JP2023198254A Active JP7798368B2 (ja) 2018-10-22 2023-11-22 Ｃｘｃｒ３の切断可能な活性化因子および使用方法
JP2025145434A Pending JP2025172140A (ja) 2018-10-22 2025-09-02 Ｃｘｃｒ３の切断可能な活性化因子および使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023198254A Active JP7798368B2 (ja) 2018-10-22 2023-11-22 Ｃｘｃｒ３の切断可能な活性化因子および使用方法
JP2025145434A Pending JP2025172140A (ja) 2018-10-22 2025-09-02 Ｃｘｃｒ３の切断可能な活性化因子および使用方法

Country Status (12)

Country Link
US (2) US12110316B2 (enExample)
EP (1) EP3870212A4 (enExample)
JP (3) JP7426121B2 (enExample)
KR (1) KR20210081372A (enExample)
CN (2) CN120022352A (enExample)
AU (2) AU2019365654B2 (enExample)
BR (1) BR112021007414A2 (enExample)
CA (1) CA3116325A1 (enExample)
IL (2) IL324815A (enExample)
MX (1) MX2021004496A (enExample)
SG (1) SG11202103497WA (enExample)
WO (1) WO2020086400A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024009210A (ja) * 2018-10-22 2024-01-19 ユニバーシティ オブ ピッツバーグ － オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション Ｃｘｃｒ３の切断可能な活性化因子および使用方法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202208950D0 (en) * 2022-06-17 2022-08-10 Ucl Business Ltd Treatment of the corneal endothelium
WO2024118744A2 (en) * 2022-11-30 2024-06-06 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Coacervate formulations of cxcr3-activating peptides for controlled release in ophthalmic and topical treatments

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003526315A (ja) 1997-10-22 2003-09-09 ジェネティックス・インスチチュート・リミテッド・ライアビリティ・カンパニー アミノ末端修飾を有するケモカイン
WO2013032853A1 (en) 2011-08-26 2013-03-07 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Activators of cxcr3 for the treatment of angiopathies of the eye

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994292A (en) * 1995-05-31 1999-11-30 The United States Of America As Represented By The Department Of Health And Human Services Interferon-inducible protein 10 is a potent inhibitor of angiogenesis
US20070116669A1 (en) * 2002-09-13 2007-05-24 Chemokine Therapeutics Corporation Interferon-inducible protein-10 (IP-10 or CXCL10) chemokine analogs for the treatment of human diseases
GB2377444A (en) 2001-04-09 2003-01-15 Smithkline Beecham Plc Chemokine-family polypeptide
IL164942A0 (en) * 2004-10-31 2005-12-18 Yeda Res & Dev The use of a protease or a protease inhibitor for the manufacture of medicaments
US8734775B2 (en) 2011-08-26 2014-05-27 University Of Pittsburgh Chemokine derived peptides that bind with chemokine receptor CXCR3 and uses for chronic wound and angiogenesis inhibition treatments
AU2014306074B2 (en) * 2013-08-05 2018-08-30 Greenlight Biosciences, Inc. Engineered proteins with a protease cleavage site
US9895419B2 (en) * 2014-01-21 2018-02-20 University of Pittsburgh—of the Commonwealth System of Higher Education Goblet cell replacement therapy
ES2738582T3 (es) * 2014-02-14 2020-01-23 Immune Design Corp Inmunoterapia del cáncer a través de combinación de inmunoestimulación local y sistémica
AU2017290828A1 (en) * 2016-06-30 2019-01-24 Virogin Biotech Canada Ltd Pseudotyped oncolytic viral delivery of therapeutic polypeptides
JP7626577B2 (ja) 2016-11-28 2025-02-07 中外製薬株式会社 リガンド結合活性が調整可能なリガンド結合分子
SG11201909160WA (en) * 2017-04-11 2019-10-30 Inhibrx Inc Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
KR20210081372A (ko) 2018-10-22 2021-07-01 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 절단 가능한 cxcr3의 활성제 및 이의 사용 방법

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003526315A (ja) 1997-10-22 2003-09-09 ジェネティックス・インスチチュート・リミテッド・ライアビリティ・カンパニー アミノ末端修飾を有するケモカイン
WO2013032853A1 (en) 2011-08-26 2013-03-07 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Activators of cxcr3 for the treatment of angiopathies of the eye

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NOMIYAMA H et al.，"Systematic classification of vertebrate chemokines based on conserved synteny and evolutionary history."，Genes to cells : devoted to molecular & cellular mechanisms，2012年，Vol. 18, No. 1，pp. 1-16

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024009210A (ja) * 2018-10-22 2024-01-19 ユニバーシティ オブ ピッツバーグ － オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション Ｃｘｃｒ３の切断可能な活性化因子および使用方法
JP7798368B2 (ja) 2018-10-22 2026-01-14 ユニバーシティ オブ ピッツバーグ － オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション Ｃｘｃｒ３の切断可能な活性化因子および使用方法

Also Published As

Publication number Publication date
EP3870212A1 (en) 2021-09-01
SG11202103497WA (en) 2021-05-28
JP2022512770A (ja) 2022-02-07
US20250002549A1 (en) 2025-01-02
BR112021007414A2 (pt) 2021-08-10
US20210388048A1 (en) 2021-12-16
JP2025172140A (ja) 2025-11-20
IL282431A (en) 2021-06-30
EP3870212A4 (en) 2022-11-16
AU2019365654A1 (en) 2021-05-13
JP7798368B2 (ja) 2026-01-14
CN113038965A (zh) 2021-06-25
IL324815A (en) 2026-01-01
IL282431B2 (en) 2026-04-01
AU2019365654A8 (en) 2021-05-20
WO2020086400A1 (en) 2020-04-30
CN120022352A (zh) 2025-05-23
US12110316B2 (en) 2024-10-08
KR20210081372A (ko) 2021-07-01
JP2024009210A (ja) 2024-01-19
CN113038965B (zh) 2025-02-07
AU2025200880A1 (en) 2025-03-06
AU2019365654B2 (en) 2024-11-14
IL282431B1 (en) 2025-12-01
MX2021004496A (es) 2021-06-04
CA3116325A1 (en) 2020-04-30

Similar Documents

Publication Publication Date Title
JP7798368B2 (ja) Ｃｘｃｒ３の切断可能な活性化因子および使用方法
JP7117012B2 (ja) 糖尿病網膜症を予防または治療するための方法
JP6124943B2 (ja) Ｓａｐ変異体及びその使用
JP2026002845A (ja) 眼の感染症および疾患を処置するための組成物および方法
JP2012530714A5 (enExample)
JP7194440B2 (ja) 心臓病変を改善するための方法
JP7455457B2 (ja) 筋萎縮性側索硬化症を治療するための方法と薬剤
BG107685A (bg) Хемокинови мутанти за лечение на мултиплена склероза
US20100150872A1 (en) Polypeptides derived from the hemopexin-like domain of metalloproteinase mmp-2
HK40123732A (zh) Cxcr3的可切割激活剂及其使用方法
HK40055610A (en) Cleavable activator of cxcr3 and use method thereof
HK40055610B (zh) Cxcr3的可切割激活剂及其使用方法
CN103897034B (zh) 一种预防和/或治疗炎症反应的小分子多肽及其应用
WO2007105199A1 (en) Use of caspases for the preparation of medicaments
HK1240129A1 (en) Method for preventing or treating diabetic retinopathy
Class et al. Patent application title: POLYPEPTIDES DERIVED FROM THE HEMOPEXIN-LIKE DOMAIN OF METALLOPROTEINASE MMP-2 Inventors: Andreas Bikfalvi (Gradignan, FR) Carlo Sala (Milano, IT) Lorenzo Bello (Torino, IT)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221006

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221006

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230822

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231122

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231221

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240115

R150 Certificate of patent or registration of utility model

Ref document number: 7426121

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150